Overview

Clinical Trial of Ambroxol in Patients With Type I Gaucher Disease

Status:
Suspended
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
Ambroxol is expected to improve the signs and symptoms of patients with Type I Gaucher Disease.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Exsar Corporation
Treatments:
Ambroxol